Implementation of the guideline’s recommendations will prevent iatrogenic visual loss. The new guideline also makes recommendations regarding the techniques and timing of baseline and follow-up screening tests for both hydroxychloroquine and chloroquine retinopathy. Cellulitis from plaquenil Botox and plaquenil Screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 92 2011;1182415-22. 93 5. Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF, American Academy of O. 94 Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy 2016 95 Revision. Ophthalmology. 2016. 96 6. No single imaging platform can confirm the presence of hydroxychloroquine toxicity, but a combination of imaging tests can provide ample evidence for diagnosis. • Microperimetry and adaptive optics are undergoing studies to confirm their usefulness in hydroxychloroquine toxicity screening. In particular, chloroquine and hydroxychloroquine Plaquenil are two such medications, with the potential for retinal toxicity. Given that the retinal damage from these medications is largely irreversible, screening by a retinal specialist is critical to detect early retinal toxicity to try and limit the extent of visual loss. In general, hydroxychloroquine is a safe and cost-effective medication, particularly when compared to newer anti-inflammatory medicines which can more significant adverse effects on the body. Hydroxychloroquine is a medicine that is effective in treating various long-term inflammatory disorders of the joints and skin. Hydroxychloroquine retinal toxicity screening Hydroxychloroquine And Chloroquine Screening 2016 AAO., Retina Today - Imaging in Hydroxychloroquine Toxicity April 2019 Plaquenil drug namePlaquenil e alopecia Hydroxychloroquine retinopathy It is known that some people who take hydroxychloroquine for more than five years and/or in high doses are at increased risk of damage to their retina, the light sensitive layer of cells at the back of the eye. This is known as retinal toxicity or retinopathy. Overall, around seven patients out of every 100 Eye screening for patients taking hydroxychloroquine Plaquenil. Retinal Screening for Hydroxychloroquine Plaquenil Toxicity. Hydroxychloroquine and Chloroquine Retinopathy.. Screening methods still vary among clinicians but have evolved over the last decade 1, 2 and the optimal dose of hydroxychloroquine HCQ is now set at ≤5 mg/kg real body weight, above which the risk of retinal toxicity increases 3. Ocular findings of HCQ retinal toxicity as detected by various screening modalities. A female patient was diagnosed with HCQ retinal toxicity at the age of 53 years, having taken HCQ for 12 years at 400 mg/day. She was not obese and had no additional risk factors for toxicity. Since the initial screening and monitoring recommendations were published in 2002, there have been reports of retinal toxicity associated with the use of Plaquenil. Furthermore, the advent of novice sensitive diagnostic modalities has led to a revision of the recommended guidelines for patients using Plaquenil see “2011 Plaquenil Screening.